Levosert (Levonorgestrel)

Levonorgestrel released from the intrauterine system acts on the endometrium, cervical mucus and ovary. It suppresses ovulation, thickens cervical mucus to impede sperm passage, and induces endometrial atrophy, creating an environment that prevents implantation and reduces menstrual bleeding.

The dosing regimen of Levosert is determined by the prescribing clinician. The device contains 52 mg of levonorgestrel and releases approximately 20 µg per day for up to five years; the prescriber decides insertion timing and follow‑up schedule based on individual patient needs.

Levosert is classified as pregnancy category X; it must not be used in women who are pregnant or who intend to become pregnant. Breastfeeding is not a contraindication after insertion, but women should discuss any concerns with their healthcare provider, as hormonal exposure may affect milk production.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with combined oral contraceptives, Levosert offers a “set‑and‑forget” approach with continuous low‑dose levonorgestrel release, eliminating daily adherence. Unlike copper IUDs, it reduces menstrual bleeding and may improve anemia, but it does not protect against sexually transmitted infections.

Store Levosert at room temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture and direct sunlight. Do not attempt to open or manipulate the intrauterine system before insertion by a qualified healthcare professional.

Levosert is inserted into the uterine cavity by a trained clinician using a specialized inserter. The procedure is performed in a clinical setting under aseptic conditions, typically during the early follicular phase of the menstrual cycle. Once placed, the device remains effective for up to five years without further dosing.

Serious but uncommon risks include uterine perforation during insertion, expulsion of the device, pelvic inflammatory disease, and ectopic pregnancy if contraception fails. Users should seek immediate medical attention for severe abdominal pain, abnormal bleeding, or signs of infection.

Levosert is contraindicated in women who are pregnant, have current or suspected pelvic infection, unexplained vaginal bleeding, known or suspected uterine malignancy, or a history of severe allergic reaction to levonorgestrel. It should also be avoided in individuals with active liver disease or known hypersensitivity to the device components.